Authors
Shu Xing, Yayue Tan, Xinyi Lu, Caichuan Yan, Duo Zhi
Published in
Tissue & cell. Volume 105. Pages 104136. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
Platinum resistance remains the major obstacle in ovarian cancer treatment, yet the role of lipid metabolism regulators in chemo-resistance mechanisms is not well understood. To address this, this study combined computational and experimental approaches to identify FABP4 as a candidate factor associated with platinum resistance through ferroptosis suppression. Transcriptomic data from GSE51373 were analyzed using limma for differential expression, and machine learning algorithms (XGBoost/Lasso/Random Forest) were employed to prioritize resistance-associated genes. Platinum-resistant ovarian cancer cell lines (Resistance Index,RI=3.8) were established by pulse exposure to increasing cisplatin concentrations (0.5-10 μM) over 6 months for functional validation. In vitro assays, including CCK-8 proliferation,Annexin V/PI apoptosis detection, ROS detection, ferroptosis markers (GPX4 activity/MDA/Western blot), and shRNA-mediated FABP4 knockdown, were performed, and the therapeutic potential was evaluated in BALB/c nude mouse xenografts. The results showed that multi-algorithm screening identified FABP4 as a top platinum resistance biomarker (AUC=0.861,95% CI: 0.782-0.940). TCGA survival analysis further revealed that high FABP4 expression was significantly associated with worse prognosis in ovarian cancer. Experimentally, FABP4 was upregulated in resistant cells (p < 0.01), and its knockdown suppressed proliferation (p < 0.01) and tumor growth (p < 0.001). Mechanistically, FABP4 was associated with reduced intracellular ROS and alterations in ferroptosis markers, as demonstrated by increased GPX4 activity and SLC7A11 expression and decreased lipid peroxidation (MDA reduced 35%, p < 0.01) in resistant cells. Notably, FABP4 knockdown increased cisplatin-induced apoptosis and elevated ROS levels. In conclusion, FABP4 is associated with platinum resistance and correlates with ROS-dependent ferroptosis marker alterations, and may restore chemosensitivity, offering a potential therapeutic strategy for refractory ovarian cancer.
PMID:
43033555
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0